340 related articles for article (PubMed ID: 9010986)
1. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
Chevallier B; Cappelaere P; Splinter T; Fabbro M; Wendling JL; Cals L; Catimel G; Giovannini M; Khayat D; Bastit P; Claverie N
Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting.
Fauser AA; Pizzocaro G; Schueller J; Khayat D; Wilkinson P
Support Care Cancer; 2000 Jan; 8(1):49-54. PubMed ID: 10650898
[TBL] [Abstract][Full Text] [Related]
5. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy.
Yeilding A; Bertoli L; Eisenberg P; Plezia P; Modiano MR; Alberts DS; Khojasteh A; Cramer MB; Hahne WF
Am J Clin Oncol; 1996 Dec; 19(6):619-23. PubMed ID: 8931684
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Fauser AA; Duclos B; Chemaissani A; Del Favero A; Cognetti F; Diaz-Rubio E; Cortes-Funes H; Conte PF; Dressler H
Eur J Cancer; 1996 Aug; 32A(9):1523-9. PubMed ID: 8911112
[TBL] [Abstract][Full Text] [Related]
7. Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.
Balfour JA; Goa KL
Drugs; 1997 Aug; 54(2):273-98. PubMed ID: 9257083
[TBL] [Abstract][Full Text] [Related]
8. Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.
Diemunsch P; D'Hollander A; Paxton L; Schoeffler P; Wessel P; Navé S; Brown RA; Hahne WF
J Clin Anesth; 1997 Aug; 9(5):365-73. PubMed ID: 9257201
[TBL] [Abstract][Full Text] [Related]
9. Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group.
Conroy T; Cappelaere P; Fabbro M; Fauser AA; Splinter TA; Spielmann M; Schneider M; Chevallier B; Goupil A; Chauvergne J
Am J Clin Oncol; 1994 Apr; 17(2):97-102. PubMed ID: 8141114
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients.
Bey P; Wilkinson PM; Resbeut M; Bourdin S; Le Floch O; Hahne W; Claverie N
Support Care Cancer; 1996 Sep; 4(5):378-83. PubMed ID: 8883232
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
[TBL] [Abstract][Full Text] [Related]
12. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.
Hesketh PJ; Gandara DR; Hesketh AM; Facada A; Perez EA; Webber LM; Martin LA; Cramer MB; Hahne WF
Support Care Cancer; 1996 Mar; 4(2):141-6. PubMed ID: 8673351
[TBL] [Abstract][Full Text] [Related]
13. Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
Korttila K; Clergue F; Leeser J; Feiss P; Olthoff D; Payeur-Michel C; Wessel P; Nave S; Hahne W; Brown R
Acta Anaesthesiol Scand; 1997 Aug; 41(7):914-22. PubMed ID: 9265937
[TBL] [Abstract][Full Text] [Related]
14. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
15. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
[TBL] [Abstract][Full Text] [Related]
16. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
Lofters WS; Pater JL; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
J Clin Oncol; 1997 Aug; 15(8):2966-73. PubMed ID: 9256141
[TBL] [Abstract][Full Text] [Related]
17. Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting.
Diemunsch P; Leeser J; Feiss P; D'Hollander A; Bradburn BG; Paxton D; Whitmore J; Panouillot P; Navé S; Brown RA; Hahne WF
Can J Anaesth; 1997 Feb; 44(2):173-81. PubMed ID: 9043731
[TBL] [Abstract][Full Text] [Related]
18. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
19. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.
Kris MG; Grunberg SM; Gralla RJ; Baltzer L; Zaretsky SA; Lifsey D; Tyson LB; Schmidt L; Hahne WF
J Clin Oncol; 1994 May; 12(5):1045-9. PubMed ID: 8164028
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
Coppes MJ; Yanofsky R; Pritchard S; Leclerc JM; Howard DR; Perrotta M; Keays S; Pyesmany A; Dempsey E; Pratt CB
J Pediatr Hematol Oncol; 1999; 21(4):274-83. PubMed ID: 10445889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
